Ionis Pharmaceuticals (NASDAQ:IONS) Director B Lynne Parshall Sells 5,000 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director B Lynne Parshall sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $82.72, for a total value of $413,600.00. Following the sale, the director owned 56,344 shares of the company’s stock, valued at approximately $4,660,775.68. This represents a 8.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ionis Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ:IONS traded down $1.18 on Friday, reaching $80.60. The company had a trading volume of 1,931,186 shares, compared to its average volume of 2,192,453. Ionis Pharmaceuticals, Inc. has a 52-week low of $23.95 and a 52-week high of $86.74. The firm’s 50 day simple moving average is $80.70 and its 200-day simple moving average is $69.12. The firm has a market capitalization of $13.05 billion, a PE ratio of -47.69 and a beta of 0.29. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Royal Bank Of Canada increased their price target on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Barclays started coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $95.00 price objective for the company. Leerink Partners raised their target price on shares of Ionis Pharmaceuticals from $85.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Bank of America upped their price target on Ionis Pharmaceuticals from $86.00 to $97.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Morgan Stanley increased their price objective on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $86.95.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Brown Brothers Harriman & Co. acquired a new stake in shares of Ionis Pharmaceuticals during the fourth quarter worth $27,000. Golden State Wealth Management LLC raised its stake in Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after acquiring an additional 250 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $25,000. Mather Group LLC. acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $27,000. Finally, Quarry LP purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at about $38,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.